Top

Published in:

Open Access 01-01-2016 | Clinical Study

Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide

Authors: Johan A. F. Koekkoek, Linda Dirven, Jan J. Heimans, Tjeerd J. Postma, Maaike J. Vos, Jaap C. Reijneveld, Martin J. B. Taphoorn

Published in: Journal of Neuro-Oncology | Issue 2/2016

Abstract

We aimed to analyze the value of seizure reduction and radiological response as prognostic markers of survival in patients with low-grade glioma (LGG) treated with temozolomide (TMZ) chemotherapy. We retrospectively reviewed adult patients with a progressive LGG and uncontrolled epilepsy in two hospitals (VUmc Amsterdam; MCH The Hague), who received chemotherapy with TMZ between 2002 and 2014. End points were a ≥50 % seizure reduction and MRI response 6, 12 and 18 months (mo) after the start of TMZ, and their relation with progression-free survival (PFS) and overall survival (OS). We identified 53 patients who met the inclusion criteria. Seizure reduction was an independent prognostic factor for both PFS (HR 0.38; 95 % CI 0.19–0.73; p = 0.004) and OS (HR 0.39; 95 % CI 0.18–0.85; p = 0.018) after 6mo, adjusting for age and histopathological diagnosis, as well as after 12 and 18mo. Patients with an objective radiological response showed a better OS (median 87.5mo; 95 % CI 62.0–112.9) than patients without a response (median 34.4mo; 95 % CI 26.1–42.6; p = 0.046) after 12mo. However, after 6 and 18mo OS was similar in patients with and without a response on MRI. Seizure reduction is an early and consistent prognostic marker for survival after treatment with TMZ, that seems to precede the radiological response. Therefore, seizure reduction may serve as a surrogate marker for tumor response.

Available only for authorised users

Schiff D, Brown PD, Giannini C (2007) Outcome in adult low-grade glioma: the impact of prognostic factors and treatment. Neurology 69(13):1366–1373PubMedCrossRef

Weiler M, Wick W (2012) Molecular predictors of outcome in low-grade glioma. Curr Opin Neurol 25(6):767–773PubMedCrossRef

Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P et al (2002) Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20(8):2076–2084PubMedCrossRef

Chang EF, Smith JS, Chang SM, Lamborn KR, Prados MD, Butowski N et al (2008) Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. J Neurosurg 109(5):817–824PubMedCrossRef

Veeravagu A, Jiang B, Ludwig C, Chang SD, Black KL, Patil CG (2013) Biopsy versus resection for the management of low-grade gliomas. Cochrane Database Syst Rev 4:CD009319PubMed

Ricard D, Kaloshi G, Amiel-Benouaich A, Lejeune J, Marie Y, Mandonnet E et al (2007) Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol 61(5):484–490PubMedCrossRef

Butowski N, Chang SM (2012) Endpoints for clinical trials and revised assessment in neuro-oncology. Curr Opin Neurol 25(6):780–785PubMedCrossRef

van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L et al (2011) Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 12(6):583–593PubMedCrossRef

Kerkhof M, Vecht CJ (2013) Seizure characteristics and prognostic factors of gliomas. Epilepsia 54(Suppl 9):12–17PubMedCrossRef

10.

de Groot M, Reijneveld JC, Aronica E, Heimans JJ (2012) Epilepsy in patients with a brain tumour: focal epilepsy requires focused treatment. Brain 135(Pt 4):1002–1016PubMedCrossRef

11.

Rudà R, Bello L, Duffau H, Soffietti R (2012) Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments. Neuro Oncol 14(Suppl 4):iv55–iv64PubMedPubMedCentralCrossRef

12.

Soffietti R, Rudà R, Bradac GB, Schiffer D (1998) PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 43(5):1066–1073PubMedCrossRef

13.

Pace A, Vidiri A, Galie E, Carosi M, Telera S, Cianciulli AM et al (2003) Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol 14(12):1722–1726PubMedCrossRef

14.

Sherman JH, Moldovan K, Yeoh HK, Starke RM, Pouratian N, Shaffrey ME et al (2011) Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas. J Neurosurg 114(6):1617–1621PubMedCrossRef

15.

Rudà R, Magliola U, Bertero L, Trevisan E, Bosa C, Mantovani C et al (2013) Seizure control following radiotherapy in patients with diffuse gliomas: a retrospective study. Neuro Oncol 15(12):1739–1749PubMedPubMedCentralCrossRef

16.

Kaloshi G, Benouaich-Amiel A, Diakite F, Taillibert S, Lejeune J, Laigle-Donadey F et al (2007) Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 68(21):1831–1836PubMedCrossRef

17.

Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J et al (2004) Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 22(15):3133–3138PubMedCrossRef

18.

Stege EM, Kros JM, de Bruin HG, Enting RH, van Heuvel I, Looijenga LH et al (2005) Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 103(4):802–809PubMedCrossRef

19.

Brada M, Viviers L, Abson C, Hines F, Britton J, Ashley S et al (2003) Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 14(12):1715–1721PubMedCrossRef

20.

Koekkoek JA, Dirven L, Heimans JJ, Postma TJ, Vos MJ, Reijneveld JC et al (2014) Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide. J Neurol Neurosurg Psychiatry 86(4):366–373PubMedCrossRef

21.

Viaccoz A, Lekoubou A, Ducray F (2012) Chemotherapy in low-grade gliomas. Curr Opin Oncol 24(6):694–701PubMedCrossRef

22.

Peyre M, Cartalat-Carel S, Meyronet D, Ricard D, Jouvet A, Pallud J et al (2010) Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. Neuro Oncol 12(10):1078–1082PubMedPubMedCentralCrossRef

23.

Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277–1280PubMed

24.

Taphoorn MJ, Klein M (2004) Cognitive deficits in adult patients with brain tumours. Lancet Neurol 3(3):159–168PubMedCrossRef

25.

Aaronson NK, Taphoorn MJ, Heimans JJ, Postma TJ, Gundy CM, Beute GN et al (2011) Compromised health-related quality of life in patients with low-grade glioma. J Clin Oncol 29(33):4430–4435PubMedCrossRef

26.

Klein M, Engelberts NH, van der Ploeg HM, Kasteleijn-Nolst Trenite DG, Aaronson NK, Taphoorn MJ et al (2003) Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann Neurol 54(4):514–520PubMedCrossRef

27.

Tosoni A, Franceschi E, Ermani M, Bertorelle R, Bonaldi L, Blatt V et al (2008) Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. J Neurooncol 89(2):179–185PubMedCrossRef

28.

Rogers LR, Morris HH, Lupica K (1993) Effect of cranial irradiation on seizure frequency in adults with low-grade astrocytoma and medically intractable epilepsy. Neurology 43(8):1599–1601PubMedCrossRef

29.

van den Bent MJ, Afra D, De WO, Ben HM, Schraub S, Hoang-Xuan K et al (2005) Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366(9490):985–990PubMedCrossRef

30.

Ciceroni C, Bonelli M, Mastrantoni E, Niccolini C, Laurenza M, Larocca LM et al (2013) Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas. Cell Death Differ 20(3):396–407PubMedPubMedCentralCrossRef

31.

Shamji MF, Fric-Shamji EC, Benoit BG (2009) Brain tumors and epilepsy: pathophysiology of peritumoral changes. Neurosurg Rev 32(3):275–284PubMedCrossRef

32.

Chang EF, Potts MB, Keles GE, Lamborn KR, Chang SM, Barbaro NM et al (2008) Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg 108(2):227–235PubMedCrossRef

33.

Hildebrand J, Lecaille C, Perennes J, Delattre JY (2005) Epileptic seizures during follow-up of patients treated for primary brain tumors. Neurology 65(2):212–215PubMedCrossRef

34.

Jung TY, Jung S, Moon JH, Kim IY, Moon KS, Jang WY (2011) Early prognostic factors related to progression and malignant transformation of low-grade gliomas. Clin Neurol Neurosurg 113(9):752–757PubMedCrossRef

Title: Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide
Authors: Johan A. F. Koekkoek
Linda Dirven
Jan J. Heimans
Tjeerd J. Postma
Maaike J. Vos
Jaap C. Reijneveld
Martin J. B. Taphoorn
Publication date: 01-01-2016
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2016
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-015-1975-y

2024 ASCO Annual Meeting

Springer Medicine

Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2016

AshwaMAX and Withaferin A inhibits gliomas in cellular and murine orthotopic models

Leukoencephalopathy in long term brain metastases survivors treated with radiosurgery

CogState computerized memory tests in patients with brain metastases: secondary endpoint results of NRG Oncology RTOG 0933

Therapeutic potential of cyclooxygenase-3 inhibitors in the management of glioblastoma

Impact of cognitive function on communication in patients with primary or secondary brain tumours

Development of brain metastases in patients with metastatic melanoma while receiving ipilimumab